RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-3.24%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$5.73B
AUM Growth
+$5.73B
(-15%)
Cap. Flow
-$198M
Cap. Flow
% of AUM
-3.45%
Top 10 Holdings %
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16
Top Buys
| 1 |
Invivyd
IVVD
|
$137M |
| 2 |
Absci
ABSI
|
$93.4M |
| 3 |
LivaNova
LIVN
|
$85.5M |
| 4 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
$49.2M |
| 5 |
Stevanato
STVN
|
$30M |
Top Sells
| 1 |
DexCom
DXCM
|
$98.4M |
| 2 |
ZY
Zymergen Inc. Common Stock
ZY
|
$60.9M |
| 3 |
SelectQuote
SLQT
|
$46.5M |
| 4 |
Charles River Laboratories
CRL
|
$40.1M |
| 5 |
Cigna
CI
|
$37.9M |
Sector Composition
| 1 | Healthcare | 93.97% |
| 2 | Consumer Staples | 3.39% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PPD
76
DELISTED
PPD, Inc. Common Stock
PPD
| – | – |
-466,471
| Closed | -$21.5M |
|
|
ZY
77
DELISTED
Zymergen Inc. Common Stock
ZY
| – | – |
-1,522,900
| Closed | -$60.9M |
|
|
TLIS
78
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
| – | – |
-363,849
| Closed | -$4.01M |
|
|
CTLT
79
DELISTED
CATALENT, INC.
CTLT
| – | – |
-310,111
| Closed | -$33.5M |
|
80
Zentalis Pharmaceuticals
ZNTL
$123M
| – | – |
-425,480
| Closed | -$22.6M |
|
81
Treace Medical Concepts
TMCI
$458M
| – | – |
-323,765
| Closed | -$10.1M |
|
82
Neuronetics
STIM
$216M
| – | – |
-394,355
| Closed | -$6.32M |
|
|
83
SelectQuote
SLQT
$366M
| – | – |
-2,411,957
| Closed | -$46.5M |
|
84
Quanterix
QTRX
$202M
| – | – |
-240,933
| Closed | -$14.1M |
|
85
Quantum-Si Incorporated
QSI
$217M
| – | – |
-1,700,000
| Closed | -$20.8M |
|
86
InnovAge Holding
INNV
$509M
| – | – |
-843,578
| Closed | -$18M |
|
|
87
DexCom
DXCM
$30.9B
| – | – |
-230,558
| Closed | -$98.4M |
|
|
88
Charles River Laboratories
CRL
$7.99B
| – | – |
-108,374
| Closed | -$40.1M |
|
|
89
Cigna
CI
$80.2B
| – | – |
-159,727
| Closed | -$37.9M |
|
90
Atea Pharmaceuticals
AVIR
$275M
| – | – |
-237,360
| Closed | -$5.1M |
|
91
Ardelyx
ARDX
$1.57B
| – | – |
-3,714,100
| Closed | -$28.2M |
|